|
1
|
Drzewiecka D: Significance and roles of
proteus spp. Bacteria in natural environments. Microb Ecol.
72:741–758. 2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Mobley HLT: Proteus mirabilis
overview. Methods Mol Biol. 2021:1–4. 2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Armbruster CE, Mobley HLT and Pearson MM:
Pathogenesis of Proteus mirabilis infection. EcoSal Plus.
8(10)2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Wasfi R, Hamed SM, Amer MA and Fahmy LI:
Proteus mirabilis Biofilm: Development and therapeutic
strategies. Front Cell Infect Microbiol. 10(414)2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Yuan F, Huang Z, Yang T, Wang G, Li P,
Yang B and Li J: Pathogenesis of Proteus mirabilis in
catheter-associated urinary tract infections. Urol Int.
105:354–361. 2021.PubMed/NCBI View Article : Google Scholar
|
|
6
|
El-Sayed Ahmed MAE, Zhong LL, Shen C, Yang
Y, Doi Y and Tian GB: . Colistin and its role in the Era of
antibiotic resistance: An extended review (2000-2019). Emerg
Microbes Infect. 9:868–885. 2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Gogry FA, Siddiqui MT, Sultan I and Haq
QMR: Current update on intrinsic and acquired colistin resistance
mechanisms in bacteria. Front Med (Lausanne).
8(677720)2021.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Vinuesa V and McConnell MJ: Recent
advances in iron chelation and gallium-based therapies for
antibiotic resistant bacterial infections. Int J Mol Sci.
22(2876)2021.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Cassini A, Högberg LD, Plachouras D,
Quattrocchi A, Hoxha A, Simonsen GS, Colomb-Cotinat M, Kretzschmar
ME, Devleesschauwer B, Cecchini M, et al: Attributable deaths and
disability-adjusted life-years caused by infections with
antibiotic-resistant bacteria in the EU and the European economic
area in 2015: A population-level modelling analysis. Lancet Infect
Dis. 19:56–66. 2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Andrews SC, Robinson AK and
Rodríguez-Quiñones F: Bacterial iron homeostasis. FEMS Microbiol
Rev. 27:215–237. 2003.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Sousa Gerós A, Simmons A, Drakesmith H,
Aulicino A and Frost JN: The battle for iron in enteric infections.
Immunology. 161:186–199. 2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Seyoum Y, Baye K and Humblot C: Iron
homeostasis in host and gut bacteria-a complex interrelationship.
Gut Microbes. 13:1–19. 2021.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Palmer LD and Skaar EP: Transition metals
and virulence in bacteria. Annu Rev Genet. 50:67–91.
2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Sassone-Corsi M, Chairatana P, Zheng T,
Perez-Lopez A, Edwards RA, George MD, Nolan EM and Raffatellu M:
Siderophore-based immunization strategy to inhibit growth of
enteric pathogens. Proc Natl Acad Sci USA. 113:13462–13467.
2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Zhou T, Winkelmann G, Dai ZY and Hider RC:
Design of clinically useful macromolecular iron chelators. J Pharm
Pharmacol. 63:893–903. 2011.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Liu ZD and Hider RC: Design of clinically
useful iron(III)-selective chelators. Med Res Rev. 22:26–64.
2022.PubMed/NCBI View
Article : Google Scholar
|
|
17
|
Byrne SL, Krishnamurthy D and
Wessling-Resnick M: Pharmacology of iron transport. Annu Rev
Pharmacol Toxicol. 53:17–36. 2013.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Kontoghiorghes GJ, Kolnagou A, Skiada A
and Petrikkos G: The role of iron and chelators on infections in
iron overload and non iron loaded conditions: Prospects for the
design of new antimicrobial therapies. Hemoglobin. 34:227–239.
2010.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Holbein BE and Mira de Orduña R: Effect of
trace iron levels and iron withdrawal by chelation on the growth of
Candida albicans and Candida vini. FEMS Microbiol
Lett. 307:19–24. 2010.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Thompson MG, Corey BW, Si Y, Craft DW and
Zurawski DV: Antibacterial activities of iron chelators against
common nosocomial pathogens. Antimicrob Agents Chemother.
56:5419–5421. 2012.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Gokarn K and Pal RB: Activity of
siderophores against drug-resistant Gram-positive and Gram-negative
bacteria. Infect Drug Resist. 11:61–75. 2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
International Organization for
Standardization (ISO): ISO 20776-1:2019(en) Susceptibility testing
of infectious agents and evaluation of performance of antimicrobial
susceptibility test devices. Part 1: Broth micro-dilution reference
method for testing the in vitro activity of antimicrobial agents
against rapidly growing aerobic bacteria involved in infectious
diseases. ISO, Geneva, Switzerland, 2019. https://www.iso.org/obp/ui/en/#iso:std:iso:20776:-1:ed-2:v2:en.
Accessed March 24, 2022.
|
|
23
|
Xu X, Xu L, Yuan G, Wang Y, Qu Y and Zhou
M: Synergistic combination of two antimicrobial agents closing each
other's mutant selection windows to prevent antimicrobial
resistance. Sci Rep. 8(7237)2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Stein C, Makarewicz O, Bohnert JA, Pfeifer
Y, Kesselmeier M, Hagel S and Pletz MW: Three dimensional
checkerboard synergy analysis of colistin, meropenem, tigecycline
against multidrug-resistant clinical Klebsiella pneumonia
isolates. PLoS One. 10(e0126479)2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Thwaites M, Hall D, Stoneburner A,
Shinabarger D, Serio AW, Krause KM, Marra A and Pillar C: Activity
of plazomicin in combination with other antibiotics against
multidrug-resistant Enterobacteriaceae. Diagn Microbiol Infect Dis.
92:338–345. 2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Clinical and Laboratory Standards
Institute (CLSI): M26-A Methods for determining bactericidal
activity of antimicrobial agents; Approved guideline. Volume 19.
CLSI, Wayne, PA, USA, 1999.
|
|
27
|
Gómez-Junyent J, Benavent E, Sierra Y, El
Haj C, Soldevila L, Torrejón B, Rigo-Bonnin R, Tubau F, Ariza J and
Murillo O: Efficacy of ceftolozane/tazobactam, alone and in
combination with colistin, against multidrug-resistant
Pseudomonas aeruginosa in an in vitro biofilm
pharmacodynamic model. Int J Antimicrob Agents. 53:612–619.
2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
The European Committee on Antimicrobial
Susceptibility Testing (EUCAST): Breakpoint tables for
interpretation of MICs and zone diameters Version 12.0, 2022.
https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_12.0_Breakpoint_Tables.pdf.
Accessed July 15, 2022.
|
|
29
|
Scott C, Arora G, Dickson K and Lehmann C:
Iron chelation in local infection. Molecules.
26(189)2021.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Soofi S, Cousens S, Iqbal SP, Akhund T,
Khan J, Ahmed I, Zaidi AK and Bhutta ZA: Effect of provision of
daily zinc and iron with several micronutrients on growth and
morbidity among young children in Pakistan: A cluster-randomised
trial. Lancet. 382:29–40. 2013.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Isanaka S, Aboud S, Mugusi F, Bosch RJ,
Willett WC, Spiegelman D, Duggan C and Fawzi WW: Iron status
predicts treatment failure and mortality in tuberculosis patients:
A prospective cohort study from Dar es Salaam, Tanzania. PLoS One.
7(e37350)2012.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Subashchandrabose S and Mobley HL: Back to
the metal age: battle for metals at the host-pathogen interface
during urinary tract infection. Metallomics. 7:935–942.
2015.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Bauckman KA and Mysorekar IU:
Ferritinophagy drives uropathogenic Escherichia coli
persistence in bladder epithelial cells. Autophagy. 12:850–863.
2016.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Mava Y, Ambe JP, Bello M, Watila I and
Nottidge VA: Urinary tract infection in febrile children with
sickle cell anaemia. West Afr J Med. 30:268–272. 2011.PubMed/NCBI
|
|
35
|
Collard KJ: Iron homeostasis in the
neonate. Pediatrics. 123:1208–1216. 2009.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Arshad M and Seed PC: Urinary tract
infections in the infant. Clin Perinatol. 42:17–28. 2015.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Matsumoto T: Urinary tract infections in
the elderly. Curr Urol Rep. 2:330–333. 2001.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Pfrimer K, Micheletto RF, Marchini JS,
Padovan GJ, Moriguti JC and Ferriolli E: Impact of aging on urinary
excretion of iron and zinc. Nutr Metab Insights. 7:47–50.
2014.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Detweiler K, Mayers D and Fletcher SG:
Bacteruria and urinary tract infections in the elderly. Urol Clin
North Am. 42:561–568. 2015.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Carver PL: The battle for iron between
humans and microbes. Curr Med Chem. 25:85–96. 2018.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Kovacevic Z, Kalinowski DS, Lovejoy DB,
Quach P, Wong J and Richardson DR: Iron chelators: Development of
novel compounds with high and selective anti-tumour activity. Curr
Drug Deliv. 7:194–207. 2010.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Iribarnegaray V, González MJ, Caetano AL,
Platero R, Zunino P and Scavone P: Relevance of iron metabolic
genes in biofilm and infection in uropathogenic Proteus
mirabilis. Curr Res Microb Sci. 2(100060)2021.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Silva B and Faustino P: An overview of
molecular basis of iron metabolism regulation and the associated
pathologies. Biochim Biophys Acta. 1852:1347–1359. 2015.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Bauckman KA, Matsuda R, Higgins CB,
DeBosch BJ, Wang C and Mysorekar IU: Dietary restriction of iron
availability attenuates UPEC pathogenesis in a mouse model of
urinary tract infection. Am J Physiol Renal Physiol. 316:F814–F822.
2019.PubMed/NCBI View Article : Google Scholar
|
|
45
|
VanEpps JS and Younger JG: Implantable
device-related infection. Shock. 46:597–608. 2016.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Vestby LK, Grønseth T, Simm R and Nesse
LL: Bacterial Biofilm and its role in the pathogenesis of disease.
Antibiotics (Basel). 9(59)2020.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Singh PK, Tack BF, McCray PB Jr and Welsh
MJ: Synergistic and additive killing by antimicrobial factors found
in human airway surface liquid. Am J Physiol Lung Cell Mol Physiol.
279:L799–L805. 2000.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Rogan MP, Taggart CC, Greene CM, Murphy
PG, O'Neill SJ and McElvaney NG: Loss of microbicidal activity and
increased formation of biofilm due to decreased lactoferrin
activity in patients with cystic fibrosis. J Infect Dis.
190:1245–1253. 2004.PubMed/NCBI View
Article : Google Scholar
|
|
49
|
Sharma P, Dube D, Sinha M, Yadav S, Kaur
P, Sharma S and Singh TP: Structural insights into the dual
strategy of recognition by peptidoglycan recognition protein,
PGRP-S: Structure of the ternary complex of PGRP-S with
lipopolysaccharide and stearic acid. PLoS One.
8(e53756)2013.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Moreau-Marquis S, O'Toole GA and Stanton
BA: Tobramycin and FDA-approved iron chelators eliminate
Pseudomonas aeruginosa biofilms on cystic fibrosis cells. Am
J Respir Cell Mol Biol. 41:305–313. 2009.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Zughaier SM and Cornelis P: Editorial:
Role of iron in bacterial pathogenesis. Front Cell Infect
Microbiol. 8(344)2018.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Kramer J, Özkaya Ö and Kümmerli R:
Bacterial siderophores in community and host interactions. Nat Rev
Microbiol. 18:152–163. 2020.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Ito A, Sato T, Ota M, Takemura M,
Nishikawa T, Toba S, Kohira N, Miyagawa S, Ishibashi N, Matsumoto
S, et al: In Vitro Antibacterial Properties of Cefiderocol, a Novel
Siderophore Cephalosporin, against Gram-Negative Bacteria.
Antimicrob Agents Chemother. 62:e01454–e01417. 2017.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Sheldon JR and Heinrichs DE: Recent
developments in understanding the iron acquisition strategies of
gram positive pathogens. FEMS Microbiol Rev. 39:592–630.
2015.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Sabnis A, Hagart KL, Klöckner A, Becce M,
Evans LE, Furniss RCD, Mavridou DA, Murphy R, Stevens MM, Davies
JC, et al: Colistin kills bacteria by targeting lipopolysaccharide
in the cytoplasmic membrane. Elife. 10(e65836)2021.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Plachouras D, Karvanen M, Friberg LE,
Papadomichelakis E, Antoniadou A, Tsangaris I, Karaiskos I,
Poulakou G, Kontopidou F, Armaganidis A, et al: Population
pharmacokinetic analysis of colistin methanesulfonate and colistin
after intravenous administration in critically ill patients with
infections caused by gram-negative bacteria. Antimicrob Agents
Chemother. 53:3430–3436. 2009.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Qiao J, Liu Z, Cui S, Nagy T and Xiong MP:
Synthesis and evaluation of an amphiphilic deferoxamine:
Gallium-conjugated cationic random copolymer against a murine wound
healing infection model of Pseudomonas aeruginosa. Acta
Biomater. 126:384–393. 2021.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Banin E, Brady KM and Greenberg EP:
Chelator-induced dispersal and killing of Pseudomonas
aeruginosa cells in a biofilm. Appl Environ Microbiol.
72:2064–2069. 2006.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Hancock V, Dahl M and Klemm P: Abolition
of biofilm formation in urinary tract Escherichia coli and
Klebsiella isolates by metal interference through
competition for fur. Appl Environ Microbiol. 76:3836–3841.
2010.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Zhang Y, Lin Y, Zhang X, Chen L, Xu C, Liu
S, Cao J, Zheng X, Jia H, Chen L, et al: Combining Colistin with
furanone C-30 rescues Colistin resistance of gram-negative bacteria
in vitro and in vivo. Microbiol Spectr. 9(e0123121)2021.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Mojica MF, Bonomo RA and Fast W:
B1-Metallo-β-Lactamases: Where do we stand? Curr Drug Targets.
17:1029–1050. 2016.PubMed/NCBI View Article : Google Scholar
|
